Safety, efficacy and immunogenicity of autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinoma.
Phase of Trial: Phase I
Latest Information Update: 12 May 2016
At a glance
- Drugs HSP105 peptide-loaded dendritic cell vaccine (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 08 Apr 2011 Planned end date (Mar 2012) added as reported by University Hospital Medical Information Network - Japan record.
- 13 Jul 2009 New trial record